HDL proteome: New possibilities in the treatment of cardiovascular disease

Current Vascular Pharmacology

Volumn 10, Issue 4, 2012, Pages 391-

  Burillo, Elena ^a   Civeira, Fernando ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CORONARY ARTERY DISEASE; EDITORIAL; LIPID METABOLISM; PROTEIN FUNCTION; PROTEOMICS;

ANIMALS; APOLIPOPROTEINS; CARDIOVASCULAR DISEASES; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; MOLECULAR TARGETED THERAPY; PROTEOMICS;

EID: 84859936503     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112800812773     Document Type: Editorial

References (9)

1. Gordon DJ, Rifkind BM. High-density lipoprotein--the clinical implications of recent studies. N Engl J Med 1989; 321: 1311-6.
2. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. Can J Cardiol 1988; 4 (Suppl A): 5A-10A.
3. Ginsberg HN, Elam MB, et al.; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-74.
4. Heinecke J. HDL and cardiovascular-disease risk--time for a new approach? N Engl J Med 2011; 364: 170-1.
5. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127-35.
6. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-56.
7. Escolà-Gil JC, Rotllan N, Julve J, Blanco-Vaca F. In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: new tools for predicting HDL atheroprotection. Atherosclerosis 2009; 206: 321-7.
8. Covas MI, Konstantinidou V, Fitó M. Olive oil and cardiovascular health. J Cardiovasc Pharmacol 2009; 54: 477-82.
9. Rader DJ. Illuminating HDL--is it still a viable therapeutic target? N Engl J Med 2007; 357: 2180-3.